The experienced manager will head the company’s US plant.
Schreiner Group, who specializes in labels for the pharmaceutical industry, is hiring Brian Zumbolo as the new president of its US plant in Blauvelt, NY. The position had become vacant because the previous manager, Gene Dul, had decided to retire after 15 successful years.
In the past, he has already worked in Schreiner Group's two most important markets, healthcare and mobility, most recently for a supplier in the automotive industry. He has experience in developing new markets, in acquisitions, in driving customer specifications, and in developing strong teams. For six years, he had led the Asia-Pacific business of a major US company from China.
"Schreiner Group has performed very well in the US over the past few years—now, there is the opportunity to take the business to a new level of growth and expansion," says Zumbolo. "I believe Schreiner Group still has great market potential in the United States. In the future, I see our potential as equaling that of the Schreiner Group business in Europe."
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.